Hepatitis virus

Hepatitis B and C

Among global hepatitis virus infections, hepatitis B and C account for the largest proportion. According to the estimated data by WHO, 296 million people worldwide are living with hepatitis B and 58 million are with hepatitis C. In 2019, around 1.1 million people died of these infections and their effects, including liver cancer, liver cirrhosis and other diseases caused by chronic viral hepatitis. On the positive side, all types of viral hepatitis can be controlled or prevented. Liver damage caused by hepatitis B can be prevented and the disease progression can be slowed down through medication, while hepatitis C can be cured. Timely and accurate diagnosis plays a critical role in the treatment and prevention of the hepatitis virus. As the latest and most widely used immunoassay, chemiluminescence immunoassay (CLIA) has advantages in reliability, precision, turn-around time, etc. Studies have shown that CLIA has improved specificity, greater positive predictive value, and less cross-contamination than conventional ELISA in the diagnosis of hepatitis B and hepatitis C infection. Genrui is dedicated to providing professional IVD solution to customers over the world, our POCT automatic CLIA system, Minifine 6, will be launched soon to benefit patients worldwide.

For more details, please contact us

Add:4-10F, Building 3, Geya Technology Park, Guangming District, 518106, Shenzhen, China

Tel: +86 755 26835560/1/2 Fax: +86 755 26678789

Website: http://www.genrui-bio.com/

Email: info@genrui-bio.com